[6-K] I-MAB American Current Report (Foreign Issuer)

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Analyzing...

07/17/2025 - 07:05 AM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

I-Mab

NASDAQ:IMAB

IMAB Rankings

#7106 Ranked by Market Cap

N/A Ranked by Dividends

IMAB Latest News

Jul 17, 2025

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Jul 14, 2025

I-Mab to Present at the BTIG Virtual Biotechnology Conference

Jul 2, 2025

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jun 30, 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 26, 2025

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

IMAB Latest SEC Filings

Jul 11, 2025

[6-K] I-MAB American Current Report (Foreign Issuer)

Jul 11, 2025

[424B5] I-MAB American Prospectus Supplement (Debt Securities)

Jul 11, 2025

[6-K/A] I-MAB American Amended Current Report (Foreign Issuer)

Jul 2, 2025

[6-K] I-MAB American Current Report (Foreign Issuer)

Jun 26, 2025

[6-K] I-MAB American Current Report (Foreign Issuer)

IMAB Stock Data

Market Cap 188.64M

Float 58.25M

Insiders Ownership 11.16%

Institutions Ownership 33.33%

Short Percent 1.09%

Industry Biotechnology

Sector Healthcare

Website Link

Country United States

City Rockville